GlassScriptPhysician profile
Donald Weese
NPI 1154323392
$2,401.49
in general payments reported to CMS, 2019-2025
15 companies · $1,500 in 2025
The $1,500 reported for 2025 was more than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $303 · 2020: $152 · 2022: $176 · 2023: $227 · 2024: $43.84 · 2025: $1,500.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Education: $1,727 · Food and Beverage: $43.84.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Education | $1,726.91 |
| Food and Beverage | $43.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $1,500.00 | 2025 | |
| Astellas Pharma US INC | $402.49 | 2019-2023 | |
| Coloplast Corp | $129.96 | 2019-2020 | |
| Myovant Sciences INC. | $69.04 | 2022 | |
| Abbvie INC. | $62.73 | 2019-2022 | |
| Sumitomo Pharma America, INC. | $47.86 | 2023 | Orgovyx |
| Travere Therapeutics, INC. | $33.69 | 2019 | |
| Boston Scientific Corporation | $27.72 | 2019-2020 | |
| Innovation Technologies INC | $24.85 | 2024 | Irrisept |
| Tolmar Pharmaceuticals, INC. | $23.63 | 2019 | |
| 180 Medical, INC. | $18.99 | 2024 | Gentlecath Glide |
| Endo Pharmaceuticals INC. | $17.95 | 2019 | |
| Urovant Sciences INC | $17.81 | 2022 | |
| Genzyme Corporation | $12.97 | 2019 | |
| Urogen Pharma, INC. | $11.80 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Donald Weese listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.